



ASX / Media Release
30 October 2026

September Quarterly Activities Report & Appendix 4C

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial pressure (ICP), today provides an operational and corporate update to accompany its Appendix 4C cash flow statement for the quarter ended 30 September 2026 (Q1 FY27).

Operational Update

Invex to Acquire Rekovery Therapeutics

Subsequent to the end of the quarter, as announced on 26 October 2026, Invex entered into a binding share sale and purchase agreement (**Share Purchase Agreement**) to acquire 100% of the issued share capital of Rekovery Therapeutics Limited (**Rekovery**), a New Zealand biotechnology company repurposing nalfurafine for the treatment of demyelinating diseases, including chronic optic neuropathy in patients with multiple sclerosis (**Acquisition**).

Rekovery has designed REVIVE, a Phase 2a randomised, double blind, placebo-controlled study of nalfurafine in patients with relapsing remitting multiple sclerosis and chronic optic neuropathy (**REVIVE Study**).

The consideration for the Acquisition is 45,000,000 Shares and 91,250,000 Performance Rights in three classes, which vest on the achievement of milestones relating to the REVIVE Study and the regulatory pathway for nalfurafine. No cash consideration is payable.

The Company has received firm commitments from professional and sophisticated investors for a placement of 11,250,000 Shares at an issue price of \$0.08 per Share to raise \$900,000 (before costs) (**Preliminary Placement**), to be issued under the Company's existing placement capacity.

The Company will also undertake a placement of 113,750,000 Shares at an issue price of \$0.08 per Share to raise \$9,100,000 (before costs), subject to Shareholder approval (**Placement**).

The Preliminary Placement and the Placement will together raise \$10,000,000 (before costs), to be applied principally to the REVIVE Study and the continued development of the Company's existing Exenatide assets.

Completion of the Acquisition is subject to conditions, including Shareholder approval (including under section 611 (item 7) of the Corporations Act and Listing Rule 10.1) and receipt of an Independent Expert's Report. A general meeting is expected to be held in early December 2026.

Expanded Preclinical Research Program with Tessara Therapeutics

On 24 April 2026, the Company announced the commencement of an expanded preclinical research program with Tessara Therapeutics (Tessara), evaluating Exenatide and other GLP-1 receptor agonists, including novel combination regimens, in Tessara's clinically validated human induced pluripotent stem cell (iPSC)-derived three-dimensional Alzheimer's disease model, ADBrain™.

The expanded program builds directly on prior work reported, in which Exenatide demonstrated statistically significant improvements across multiple pathologically relevant biomarkers of Alzheimer's disease (AD). In particular, Exenatide demonstrated a potential neuroprotective effect against ferroptosis — an iron-dependent oxidative cell death pathway increasingly implicated in AD neurodegeneration — representing a mechanistically differentiated finding relative to current standard-of-care therapies.

The expanded study is designed to:

- **Benchmark Exenatide against a current GLP-1 agonist** enabling direct head-to-head comparisons of two clinically active GLP-1 receptor agonists;
- **Evaluate combination regimens** of Exenatide and a current GLP-1 agonist against approved AD symptomatic treatments, exploring additive or synergistic therapeutic effects over current standards of care; and
- **Evaluate novel combination regimens** of Exenatide and a current GLP-1 agonist with naturally-occurring factors that demonstrate synergistic improvements in AD phenotype.

Tolerability and efficacy assessments will utilise Tessara's validated assay suite measuring cytotoxicity, cell viability and ferroptosis, supplemented by assays aimed at characterising the mechanistic signature of each agent and combination.

Corporate Update

Financial Summary and Analysis

The Company closed the quarter with cash and cash equivalents of \$3,591,000 (Q4 FY26: \$4,016,000), with overall operating cash outflows for the quarter of \$425,000 (Q4 FY26: \$501,000).

Cash outflows from operating expenditure included:

- Payments for Research & Development expenditure for the quarter were \$Nil (versus \$379,000 in Q4 FY26). R&D expenditure primarily relates the expansion of preclinical research program with Tessara, the variance relates to the timing of payments.
- Administration and corporate costs of \$234,000 (versus \$135,000 in Q4 FY26). The costs primarily relates to ongoing compliance costs associated with an ASX listed company and transaction costs incurred during the period.

Aggregate amounts paid to related parties of the Company and their associates included in the above costs were \$44k for the quarter.

- ENDS -

This release dated 30 October 2026 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Mr David Wheeler

Non-Executive Director

+61 8 6558 0886

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Invex Therapeutics Ltd

ABN

29 632 145 334

Quarter ended ("current quarter")

30 SEPTEMBER 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	(5)	(5)
(e) staff costs	-	-
(f) administration and corporate costs	(234)	(234)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	65	65
1.5 Interest and other costs of finance paid	(0)	(0)
1.6 Income taxes paid	-	-
1.7 R&D tax rebate	-	-
1.8 Other		
- Exclusivity Fee	(251)	(251)
1.9 Net cash (used in) operating activities	(425)	(425)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – capital return	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,016	4,016
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(425)	(425)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	3,591	3,591

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	634	1,016
5.2	Call deposits	2,957	3,000
5.3	Bank overdrafts		-
5.4	Other (provide details)		-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,591	4,016

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$A'000
(44)
-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Relates to director fees, consulting fees and registered office fees paid to Directors and Director-related entities.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9) (6 months)	(425)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	3,591
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	3,591
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	8.4

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

- Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

- Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

- Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by:
(Board of Directors)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.